Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average: 2009-2024

Historic Equity Average for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $458.9 million.

  • Ani Pharmaceuticals' Equity Average fell 2.49% to $471.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.3 million, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $458.9 million for FY2024, which is 0.02% down from last year.
  • As of FY2024, Ani Pharmaceuticals' Equity Average stood at $458.9 million, which was down 0.02% from $459.0 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Equity Average ranged from a high of $459.0 million in FY2023 and a low of $213.6 million during FY2020.
  • Moreover, its 3-year median value for Equity Average was $458.9 million (2024), whereas its average is $437.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 40.98% in 2021, then dropped by 0.02% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Equity Average (Yearly) stood at $213.6 million in 2020, then skyrocketed by 40.98% to $301.1 million in 2021, then surged by 31.48% to $395.9 million in 2022, then rose by 15.95% to $459.0 million in 2023, then fell by 0.02% to $458.9 million in 2024.